Newly released court records describe Gwendolyn White’s allegations that neighbors hacked her accounts, poisoned her soda and ...

GREENWOOD, S.C. – The Home Builders Association of South Carolina has honored Chad Charles, the president of Charles & Associates, with a Certified Master Builder designation. This program was created ...

The obesity and diabetes markets are on the cusp of transformation, driven by cutting-edge GLP-1 therapies. Eli Lilly and Novo Nordisk are shaping the competitive landscape, with novel drugs like ...

The first phase of the GLP-1 boom was defined by shortages and brand-name manufacturers sparring with compounding pharmacies. The next phase will be marked by Medicare coverage expansions and new ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. There have been many headlines in the last week about $50 weight-loss drugs for Medicare ...

Jessica Rendall is a reporter with experience covering a variety of health and wellness topics, including chronic disease, infectious disease, telemedicine, mental health and health technology. Emily ...

Ms. Belluz is a contributing Opinion writer covering health, nutrition and chronic illness. See more of our coverage in your search results.Encuentra más de nuestra cobertura en los resultados de ...

The weight-loss drug rivalry heats up as another GLP-1 pill gains FDA approval This week the U.S. Food and Drug Administration approved a second GLP-1 pill for weight loss. The drug, called Foundayo, ...

The investigative minds at How to Survive break down the ultimate survival tactics, resource strategies, and combat decisions needed during a zombie apocalypse.

The investigative minds at How to Survive examine the engineering risks and psychological pressure of crossing the world’s ...

After capturing the North American market with Wegovy (semaglutide) and Zepbound (tirzepatide), Novo Nordisk A/S and Eli Lilly and Co. are advancing blockbuster glucagon-like peptide-1 (GLP-1) ...

Injectable GLP-1s have shown slightly higher effectiveness for weight loss in clinical trials compared to oral versions. Both forms share similar gastrointestinal side effects, such as nausea and ...